Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2023-09-13 Sale |
2023-09-15 4:19 pm |
GENELUX Corp | GNLX | Szalay Aladar 10% Owner |
44,308 | $21.8 | $965,899 | 4,465,796 (Indirect Direct) |
View |
| 2023-09-13 Sale |
2023-09-14 8:18 pm |
GENELUX Corp | GNLX | Smither John W Director |
900 | $20.78 | $18,702 | 6,920 (Direct) |
View |
| 2023-09-11 Sale |
2023-09-13 7:04 pm |
GENELUX Corp | GNLX | Szalay Aladar 10% Owner |
52,616 | $22.23 | $1,169,868 | 4,510,104 (Indirect Direct) |
View |
| 2023-09-07 Sale |
2023-09-11 7:05 pm |
GENELUX Corp | GNLX | Szalay Aladar 10% Owner |
37,277 | $23.57 | $878,600 | 4,562,720 (Indirect Direct) |
View |
| 2023-08-30 Sale |
2023-08-30 7:22 pm |
GENELUX Corp | GNLX | Yu Yong VP, Clinical Trial Operations |
19,800 | $24.7 | $489,060 | 135,935 (Direct) |
View |
| 2023-08-18 Sale |
2023-08-22 4:18 pm |
GENELUX Corp | GNLX | Jewett Caroline Head of Quality |
515 | $23.73 | $12,221 | 1,135 (Direct) |
View |
| 2023-08-18 Sale |
2023-08-22 4:18 pm |
GENELUX Corp | GNLX | Smalling Ralph Head of Regulatory |
935 | $23.73 | $22,188 | 2,065 (Direct) |
View |
| 2023-08-18 Sale |
2023-08-22 4:17 pm |
GENELUX Corp | GNLX | Samuelson Doug Chief Financial Officer |
1,297 | $23.73 | $30,778 | 2,303 (Direct) |
View |
| 2023-08-18 Sale |
2023-08-22 4:16 pm |
GENELUX Corp | GNLX | Ryder Sean General Counsel |
328 | $23.73 | $7,783 | 572 (Direct) |
View |
| 2023-08-18 Sale |
2023-08-22 4:15 pm |
GENELUX Corp | GNLX | Cappello Joseph VP, Pharmaceutical Development |
3,265 | $23.73 | $77,478 | 5,735 (Direct) |
View |
| 2023-08-18 Sale |
2023-08-22 4:14 pm |
GENELUX Corp | GNLX | Yu Yong VP, Clinical Trial Operations |
3,265 | $23.73 | $77,478 | 155,735 (Direct) |
View |
| 2023-08-18 Sale |
2023-08-22 4:13 pm |
GENELUX Corp | GNLX | Zindrick Thomas President and CEO |
8,349 | $23.73 | $198,122 | 14,651 (Direct) |
View |
| 2023-01-26 Purchase |
2023-01-31 3:42 pm |
GENELUX CORP | GNLX | Zhang Qian Associate VP, Research |
200 | $6.2485 | $1,250 | 133,533 (Indirect Direct) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2023-09-11 Option Award |
2023-09-13 8:18 pm |
N/A 2033-09-10 |
GENELUX Corp | GNLX | Mirabelli Mary Director |
7,857 | $0 | 8,857 (Direct) |
View |
| 2023-09-11 Option Award |
2023-09-13 8:16 pm |
N/A 2033-09-10 |
GENELUX Corp | GNLX | Tyree James L Director |
7,857 | $0 | 16,857 (Direct) |
View |
| 2023-09-11 Option Award |
2023-09-13 8:15 pm |
N/A 2033-09-10 |
GENELUX Corp | GNLX | Thomas John Director |
7,857 | $0 | 486,857 (Direct) |
View |
| 2023-09-11 Option Award |
2023-09-13 8:14 pm |
N/A 2033-09-10 |
GENELUX Corp | GNLX | Smither John W Director |
15,367 | $0 | 16,267 (Direct) |
View |
Ownership |
2023-09-13 8:13 pm |
N/A N/A |
GENELUX Corp | GNLX | Smither John W Director |
0 | $0 | 900 (Direct) |
View |
| 2023-09-11 Option Award |
2023-09-12 4:26 pm |
N/A 2033-09-10 |
GENELUX Corp | GNLX | Ryder Sean General Counsel |
40,000 | $0 | 40,000 (Direct) |
View |
| 2023-09-11 Option Award |
2023-09-12 4:25 pm |
N/A 2033-09-10 |
GENELUX Corp | GNLX | Samuelson Doug Vice President, Finance |
40,000 | $0 | 40,000 (Direct) |
View |
| 2023-09-11 Option Award |
2023-09-12 4:24 pm |
N/A 2033-09-10 |
GENELUX Corp | GNLX | Yu Yong VP, Clinical Trial Operations |
65,000 | $0 | 65,000 (Direct) |
View |
| 2023-09-11 Option Award |
2023-09-12 4:23 pm |
N/A 2033-09-10 |
GENELUX Corp | GNLX | Cappello Joseph VP, Pharmaceutical Development |
65,000 | $0 | 65,000 (Direct) |
View |
| 2023-09-11 Option Award |
2023-09-12 4:22 pm |
N/A 2033-09-10 |
GENELUX Corp | GNLX | Smalling Ralph Head of Regulatory |
64,000 | $0 | 66,065 (Direct) |
View |
| 2023-09-11 Option Award |
2023-09-12 4:20 pm |
N/A 2033-09-10 |
GENELUX Corp | GNLX | Jewett Caroline Head of Quality |
108,000 | $0 | 109,135 (Direct) |
View |
| 2023-09-11 Option Award |
2023-09-12 4:19 pm |
N/A 2033-09-10 |
GENELUX Corp | GNLX | Zak Lourie S. Chief Financial Officer |
150,000 | $0 | 150,000 (Direct) |
View |
Ownership |
2023-07-03 5:47 pm |
N/A N/A |
GENELUX Corp | GNLX | Smalling Ralph Head of Regulatory |
0 | $0 | 3,000 (Direct) |
View |
Ownership |
2023-07-03 5:45 pm |
N/A N/A |
GENELUX Corp | GNLX | Jewett Caroline Head of Quality |
0 | $0 | 1,650 (Direct) |
View |
| 2023-02-17 Option Award |
2023-05-02 4:33 pm |
N/A N/A |
GENELUX CORP | GNLX | Tyree James L Director |
9,000 | $0 | 9,000 (Direct) |
View |
| 2023-02-17 Option Award |
2023-05-02 4:31 pm |
N/A N/A |
GENELUX CORP | GNLX | Mirabelli Mary Director |
1,000 | $0 | 1,000 (Direct) |
View |
| 2023-02-17 Option Award |
2023-05-02 4:30 pm |
N/A N/A |
GENELUX CORP | GNLX | Woodward Gabe Director |
1,000 | $0 | 12,362 (Direct) |
View |
| 2023-02-17 Option Award |
2023-05-02 4:28 pm |
N/A N/A |
GENELUX CORP | GNLX | Thomas John Director |
9,000 | $0 | 479,000 (Direct) |
View |
| 2023-02-27 Option Award |
2023-05-02 4:27 pm |
N/A N/A |
GENELUX CORP | GNLX | Zindrick Thomas President and CEO |
23,000 | $0 | 23,000 (Direct) |
View |
| 2023-02-17 Option Award |
2023-05-02 4:26 pm |
N/A N/A |
GENELUX CORP | GNLX | Zhang Qian Associate VP, Research |
6,000 | $0 | 139,533 (Direct) |
View |
| 2023-02-17 Option Award |
2023-05-02 4:25 pm |
N/A N/A |
GENELUX CORP | GNLX | Ryder Sean General Counsel |
900 | $0 | 900 (Direct) |
View |
| 2023-02-17 Option Award |
2023-05-02 4:23 pm |
N/A N/A |
GENELUX CORP | GNLX | Samuelson Doug Chief Financial Officer |
3,600 | $0 | 3,600 (Direct) |
View |
| 2023-02-17 Option Award |
2023-05-02 4:22 pm |
N/A N/A |
GENELUX CORP | GNLX | Yu Tony VP, Clinical Trial Operations |
9,000 | $0 | 159,000 (Direct) |
View |
| 2023-02-17 Option Award |
2023-05-02 4:21 pm |
N/A N/A |
GENELUX CORP | GNLX | Cappello Joseph VP, Pharmaceutical Development |
9,000 | $0 | 9,000 (Direct) |
View |
| 2023-01-30 Conversion |
2023-01-30 4:29 pm |
N/A N/A |
GENELUX CORP | GNLX | Szalay Aladar 10% Owner |
3,500,000 | $0 | 2,341,238 (Indirect) |
View |
| 2023-01-30 Conversion |
2023-01-30 4:28 pm |
N/A N/A |
GENELUX CORP | GNLX | Thomas John Director |
1,880,000 | $0 | 470,000 (Direct) |
View |